Foghorn Therapeutics's market cap is currently $331.45M. The company's EPS TTM is $-1.91; its P/E ratio is ―; Foghorn Therapeutics is scheduled to report earnings on March 6, 2025, and the estimated EPS forecast is $-0.32. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 34.16M	$ 19.23M	$ 1.32M	$ 430.00K	$ 0.00
Gross Profit	$ -75.53M	$ 19.21M	$ -6.20M	$ -57.28M	$ -1.79M
Operating Income	$ -107.91M	$ -117.14M	$ -100.73M	$ -68.53M	$ -51.08M
EBITDA	$ -104.45M	$ -113.82M	$ -96.19M	$ -66.49M	$ -48.80M
Net Income	$ -98.43M	$ -108.87M	$ -103.23M	$ -69.78M	$ -51.67M
Balance Sheet
Cash & Short-Term Investments	$ 234.06M	$ 345.80M	$ 154.29M	$ 185.77M	$ 14.98M
Total Assets	$ 285.92M	$ 404.88M	$ 519.77M	$ 255.59M	$ 22.34M
Total Debt	$ 45.07M	$ 51.51M	$ 58.33M	$ 82.00M	$ 16.63M
Net Debt	$ -35.26M	$ -294.29M	$ -42.80M	$ -10.80M	$ 1.65M
Total Liabilities	$ 363.11M	$ 404.77M	$ 422.90M	$ 109.41M	$ 110.36M
Stockholders' Equity	$ -77.19M	$ 112.00K	$ 96.87M	$ 146.19M	$ -88.02M
Cash Flow
Free Cash Flow	$ -119.33M	$ 192.40M	$ -53.56M	$ -47.47M	$ -47.30M
Operating Cash Flow	$ -118.11M	$ 193.61M	$ -50.25M	$ -31.29M	$ -46.34M
Investing Cash Flow	$ 144.45M	$ -244.32M	$ 36.17M	$ -108.91M	$ -964.00K
Financing Cash Flow	$ 1.78M	$ 1.76M	$ 22.42M	$ 217.47M	$ 23.97M

Currency in USD

Foghorn Therapeutics Earnings and Revenue History

Income Statement >

Foghorn Therapeutics Debt to Assets

Balance Sheet >

Foghorn Therapeutics Cash Flow

Cash Flow >

Foghorn Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing